Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTAMedical - Care Facilities
+$0.00 today
- Market cap
- $445.55M
- Beta
- 0.00
- P/E (TTM)
- 414.6
- EPS (TTM)
- $0.07
Volume 0.00M
Average 0.87M
MCTA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Charming Medical Limited Class A Ordinary SharesNASDAQ: MCTA
Research & Development · FY2024 · year ended Mar 2025
Research & development remains negative
FY2024 research & development was $0, compared with $0 a year earlier.
Context
- Research & development amounted to 0.0% of revenue in FY2024, unchanged from a year earlier.
- Research & development increased in 0 of the last 2 fiscal years.
- FY2024 was the highest annual figure in the 3 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2024
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2024 | 2025-03-31 | 0 | — |
| FY2023 | 2024-03-31 | 0 | — |
| FY2022 | 2023-03-31 | 0 | — |
Research & Development vs competitors
How MCTA compares with its peers on the latest reported figures
- MCTA's FY2024 research & development of $0 is the 7th highest of the 10 companies compared; the peer median is $9.34M.
- Research & development amounts to 0.0% of revenue for MCTA, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.31M | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $37.65M | +2.6% | +14.1% | 29.5% | |
| LTM Mar 2026 | $34.06M | +124.4% | +16.3% | 37.7% | |
| LTM Mar 2026 | $9.52M | +12.9% | +6.2% | 2.8% | |
| LTM Feb 2026 | $9.34M | +29.5% | +29.0% | 11.6% | |
| LTM Mar 2026 | $4 | -100.0% | — | 0.0% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding MCTA) | $9.34M | +15.2% | +16.3% | 1.4% | |
Competitors are the stored peer set for MCTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 |
|---|---|---|---|
| Revenue | 3.53M | 6.02M | 6.22M |
| Cost of Revenue | 2.04M | 2.1M | 2.04M |
| Gross Profit | 1.49M | 3.91M | 4.18M |
| Gross Margin | 42.3% | 65.1% | 67.2% |
| Research & Development | 0 | 0 | 0 |
| Selling, General & Admin | 1.66M | 2.35M | 2.32M |
| Operating Expenses | 2.02M | 2.91M | 2.79M |
| Depreciation & Amortization | 211.08K | 391.7K | 263.45K |
| EBITDA | (189.13K) | 1.42M | 1.72M |
| EBITDA Margin | -5.4% | 23.6% | 27.6% |
| Operating Income | (521.34K) | 1.01M | 1.39M |
| Operating Margin | -14.8% | 16.8% | 22.3% |
| Interest Income | 10.29K | 19.51K | 64.14K |
| Interest Expense | 20.26K | 26.05K | 20.87K |
| Other Income / Expenses | 100.87K | (5.35K) | 46.23K |
| Income Before Tax | (420.47K) | 1M | 1.44M |
| Pre-Tax Margin | -11.9% | 16.7% | 23.1% |
| Income Tax Expense | (84.86K) | 181.75K | 236.08K |
| Net Income | (305.12K) | 777.81K | 1.2M |
| Net Margin | -8.6% | 12.9% | 19.3% |
| EPS (Basic) | (0.02) | 0.05 | 0.07 |
| EPS (Diluted) | (0.02) | 0.05 | 0.07 |
| Weighted Avg Shares | 16.94M | 16.94M | 16.94M |
| Weighted Avg Shares (Diluted) | 16.94M | 16.94M | 16.94M |
Charming Medical Limited Class A Ordinary Shares
NASDAQ:MCTA
Intrinsic Alpha fair value
Locked
Current Price
$29.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.